Adjusted 12-month health care costs and utilization for patients in the Lyme disease sample with one or more post-treatment Lyme disease symptom (PTLDS)-related diagnosis, as compared to patients in Lyme disease sample with no post-treatment Lyme disease symptom-related diagnoses.

Note: Above table includes Lyme disease sample only. Lyme disease sample includes only those persons with a test order and antibiotic treatment within 30 days of the test order, a diagnosis and antibiotic treatment within 30 days of the diagnosis, or a diagnosis, test order and antibiotic treatment within 30 days. The Lyme disease sample includes only those with 18 consecutive months of enrollment, including a 6-month “clean period” of enrollment prior to Lyme disease episode in which they were neither diagnosed with nor tested for Lyme disease. Lyme disease sample restricted to persons under 65 years of age, with commercial health insurance plans
* Adjusted impact calculations based on GLM regression analysis using the Huber/White sandwich estimator of variance and adjusting for year, region, age, and sex, and controlling for high-cost non-Lyme disease-related conditions.
† Adjusted ratio calculations for outpatient and emergency visits are based on negative binomial regression analysis using the Huber/White sandwich estimator of variance and adjusting for year, region, age, and sex, and controlling for high-cost non-Lyme disease-related conditions.
Adjusted 12-month health care costs and utilization for patients in the Lyme disease sample with one or more post-treatment Lyme disease symptom (PTLDS)-related diagnosis, as compared to patients in Lyme disease sample with no post-treatment Lyme disease symptom-related diagnoses.